Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 185

1.

Biomarkers for primary biliary cholangitis: current perspectives.

Kouroumalis E, Samonakis D, Voumvouraki A.

Hepat Med. 2018 Jun 18;10:43-53. doi: 10.2147/HMER.S135337. eCollection 2018. Review.

2.

[Primary biliary cholangitis. Part 2. State of the art, diagnosis, associated diseases, treatment and prognosis].

Rodríguez Lugo DA, Coronado Tovar JJ, Solano Villamarin GA, Otero Regino W.

Rev Gastroenterol Peru. 2018 Jan-Mar;38(1):64-71. Spanish.

PMID:
29791424
3.

[Primary biliary cholangitis. Part 1. State of the art, epidemiology, physiopathology and clinical manifestations].

Rodríguez Lugo DA, Coronado Tovar JJ, Solano Villamarin GA, Otero Regino W.

Rev Gastroenterol Peru. 2017 Oct-Dec;37(4):357-364. Spanish.

PMID:
29459807
4.

Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis.

Tanaka A, Hirohara J, Nakano T, Yagi M, Namisaki T, Yoshiji H, Nakanuma Y, Takikawa H; Japan PBC Study Group (JPBCSG).

Hepatol Res. 2018 Feb 6. doi: 10.1111/hepr.13068. [Epub ahead of print]

PMID:
29405510
5.

Primary biliary cholangitis metachronously complicated with combined hepatocellular carcinoma-cholangiocellular carcinoma and hepatocellular carcinoma.

Ide R, Oshita A, Nishisaka T, Nakahara H, Aimitsu S, Itamoto T.

World J Hepatol. 2017 Dec 28;9(36):1378-1384. doi: 10.4254/wjh.v9.i36.1378.

6.

Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis.

Shin S, Moh IH, Woo YS, Jung SW, Kim JB, Park JW, Suk KT, Kim HS, Hong M, Park SH, Lee MS.

World J Gastroenterol. 2017 Oct 21;23(39):7191-7197. doi: 10.3748/wjg.v23.i39.7191.

7.

Novel strategies and therapeutic options for the management of primary biliary cholangitis.

Khanna A, Jones DE.

Therap Adv Gastroenterol. 2017 Oct;10(10):791-803. doi: 10.1177/1756283X17728669. Epub 2017 Sep 7. Review.

8.

Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis.

Polychronopoulou E, Lygoura V, Gatselis NK, Dalekos GN.

BMJ Case Rep. 2017 Sep 25;2017. pii: bcr-2017-220824. doi: 10.1136/bcr-2017-220824.

PMID:
28951510
9.

[Autoimmune hepatitis: Immunological diagnosis].

Brahim I, Brahim I, Hazime R, Admou B.

Presse Med. 2017 Nov;46(11):1008-1019. doi: 10.1016/j.lpm.2017.08.012. Epub 2017 Sep 14. Review. French.

PMID:
28919271
10.

Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece.

Gatselis NK, Zachou K, Lygoura V, Azariadis K, Arvaniti P, Spyrou E, Papadamou G, Koukoulis GK, Dalekos GN, Rigopoulou EI.

Eur J Intern Med. 2017 Jul;42:81-88. doi: 10.1016/j.ejim.2017.05.006. Epub 2017 May 20.

PMID:
28535947
11.

Comparison between real-time tissue elastography and vibration-controlled transient elastography for the assessment of liver fibrosis and disease progression in patients with primary biliary cholangitis.

Koizumi Y, Hirooka M, Abe M, Tokumoto Y, Yoshida O, Watanabe T, Nakamura Y, Imai Y, Yukimoto A, Kumagi T, Takeshita E, Ikeda Y, Hiasa Y.

Hepatol Res. 2017 Nov;47(12):1252-1259. doi: 10.1111/hepr.12861. Epub 2017 Feb 7.

PMID:
28044427
12.

Serum proteomic signatures as biomarkers of primary biliary cirrhosis diagnosis and prognosis.

Baudin B, Bruneel A, Poupon R, Vaubourdolle M.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):607-612.

PMID:
27707675
13.

A case of severe osteomalacia caused by Tubulointerstitial nephritis with Fanconi syndrome in asymptomotic primary biliary cirrhosis.

Yamaguchi S, Maruyama T, Wakino S, Tokuyama H, Hashiguchi A, Tada S, Homma K, Monkawa T, Thomas J, Miyashita K, Kurihara I, Yoshida T, Konishi K, Hayashi K, Hayashi M, Itoh H.

BMC Nephrol. 2015 Nov 11;16:187. doi: 10.1186/s12882-015-0184-4.

14.

The immunogenetics of primary biliary cirrhosis: A comprehensive review.

Webb GJ, Siminovitch KA, Hirschfield GM.

J Autoimmun. 2015 Nov;64:42-52. doi: 10.1016/j.jaut.2015.07.004. Epub 2015 Aug 3. Review.

15.

Autoimmune liver disease and concomitant extrahepatic autoimmune disease.

Muratori P, Fabbri A, Lalanne C, Lenzi M, Muratori L.

Eur J Gastroenterol Hepatol. 2015 Oct;27(10):1175-9. doi: 10.1097/MEG.0000000000000424.

PMID:
26148248
16.

Extreme hypercholesterolemia presenting with pseudohyponatremia - a case report and review of the literature.

Hussain I, Ahmad Z, Garg A.

J Clin Lipidol. 2015 Mar-Apr;9(2):260-4. doi: 10.1016/j.jacl.2014.11.007. Epub 2014 Nov 28.

PMID:
25911084
17.

Animal models of primary biliary cirrhosis.

Katsumi T, Tomita K, Leung PS, Yang GX, Gershwin ME, Ueno Y.

Clin Rev Allergy Immunol. 2015 Jun;48(2-3):142-53. doi: 10.1007/s12016-015-8482-y. Review.

PMID:
25771770
18.

Grave's Disease and Primary Biliary Cirrhosis-An Unusual and Challenging Association.

Shetty S, Rajasekaran S, Venkatakrishnan L.

J Clin Exp Hepatol. 2014 Mar;4(1):66-7. doi: 10.1016/j.jceh.2013.08.001. Epub 2013 Aug 29.

19.

Diagnosis and management of primary biliary cirrhosis.

Ali AH, Carey EJ, Lindor KD.

Expert Rev Clin Immunol. 2014 Dec;10(12):1667-78. doi: 10.1586/1744666X.2014.979792. Epub 2014 Nov 10. Review.

PMID:
25382237
20.

Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.

Tanaka A, Hirohara J, Nakanuma Y, Tsubouchi H, Takikawa H.

J Gastroenterol. 2015 Jun;50(6):675-82. doi: 10.1007/s00535-014-0998-z. Epub 2014 Sep 20.

PMID:
25239675

Supplemental Content

Loading ...
Support Center